All In Biotech

Drug Trial Radar · NCT06249152

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

A Pilot, Double-masked, Vehicle-controlled, Randomized Study to Evaluate the Safety and Tolerability of QLS-111 Versus Vehicle in Combination With Latanoprost Treatment in Subjects With Open-angle Glaucoma and/or Ocular Hypertension

Last checked: Nov 19, 2026Latest source record: Jan 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Apr 21, 2024

Primary completion

Dec 20, 2024

Study completion Dec 20, 2024

Sponsor

Lead sponsor
Qlaris Bio, Inc.Industry
Sponsor type
Industry
First posted
Feb 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Qlaris Phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in combination with latanoprost in open-angle glaucoma (OAG) and/or ocular hypertension (OHT) patients.

Conditions

  • Open-angle Glaucoma (OAG)
  • Ocular Hypertension (OHT)
  • Glaucoma

Interventions

  • QLS-111, 0.015%Drug

    QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.

  • QLS-111, 0.030%Drug

    QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.

  • QLS-111, 0.075%Drug

    QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.

  • QLS-111 vehicle ophthalmic solutionDrug

    Vehicle drops applied QPM for 14 days the BID for 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of ocular treatment-emergent adverse events (TEAEs)Time frame: 28 days
  2. Clinically significant change in visual acuityTime frame: 28 days
  3. Clinically significant change in findings on slit lamp examTime frame: 28 days
  4. Clinically significant change in findings on fundus examTime frame: 28 days
  5. Incidence of systemic (TEAEs)Time frame: 28 days
  6. Clinically significant change in blood pressureTime frame: 28 days
  7. Clinically significant change in heart rateTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Berkeley Eye Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.